Related Experiment Videos
Current management of advanced melanoma: a transformed landscape
David E Gyorki1, John Spillane, David Speakman
1Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
Abstract:
The prognosis for patients with stage IV melanoma has historically been extremely poor and there have until recently been no effective treatment options. The last 3 years have seen a seismic shift in the management of these patients with the entry to the clinic of a number of novel agents with proven efficacy. These agents fall into two main classes: molecular-targeted therapy and immunotherapy. Molecular therapies have primarily targeted the mitogen-activated protein kinase pathway, most notably with oral inhibitors targetting oncogenic BRAF. Immunotherapy agents such as ipilimumab, and more recently antibodies against PD-1 boost the host immune response against the melanoma. It is important for surgeons to be aware of these advances for a number of reasons. Firstly, to be able to inform their patients of the general options available in the event of disease progression. Secondly, these agents are currently being assessed in the adjuvant setting and are likely to demonstrate efficacy for earlier stages of disease. Finally, it is important for surgeons to be able to advocate on their patients' behalf to minimize the lag time between publication of these promising results and the availability of these agents in the clinic. Furthermore, patients with advanced melanoma should be offered participation in clinical trials in order to refine the indications for these agents to maximize their chance of benefit.
Insights
Recent advances in stage IV melanoma treatment offer new hope. Novel molecular targeted therapies and immunotherapies are improving patient outcomes and expanding treatment options for advanced melanoma.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Stage IV melanoma historically had a poor prognosis with limited effective treatments.
- Recent years have introduced novel therapies significantly altering patient management.
Purpose of the Study:
- To inform surgeons about recent therapeutic advances in stage IV melanoma.
- To highlight the importance of patient counseling and clinical trial participation.
- To emphasize the role of surgeons in advocating for timely access to new treatments.
Main Methods:
- Review of novel therapeutic agents including molecular targeted therapies and immunotherapies.
- Discussion of the mechanisms of action for BRAF inhibitors and PD-1 antibodies.
- Exploration of the current and potential future applications of these agents.
Main Results:
- Molecular therapies target the mitogen-activated protein kinase pathway, notably BRAF inhibitors.
- Immunotherapies like ipilimumab and PD-1 antibodies enhance the host immune response against melanoma.
- These agents show promise in both advanced and potentially earlier stages of melanoma.
Conclusions:
- New molecular and immunotherapy agents represent a paradigm shift in stage IV melanoma management.
- Surgeons must be aware of these treatments to counsel patients and advocate for access.
- Clinical trial participation is crucial for refining treatment indications and maximizing patient benefit.